Intravitreal injection: balancing the risks

Eye (Lond). 2007 Mar;21(3):313-6. doi: 10.1038/sj.eye.6702699.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Angiogenesis Inhibitors / administration & dosage
  • Anti-Inflammatory Agents / administration & dosage*
  • Anti-Inflammatory Agents / adverse effects
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Glucocorticoids / administration & dosage*
  • Glucocorticoids / adverse effects
  • Humans
  • Injections / methods
  • Ranibizumab
  • Retinal Diseases / drug therapy*
  • Treatment Outcome
  • Triamcinolone / administration & dosage*
  • Triamcinolone / adverse effects
  • Vitreous Body

Substances

  • Angiogenesis Inhibitors
  • Anti-Inflammatory Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Glucocorticoids
  • Triamcinolone
  • Bevacizumab
  • Ranibizumab